218 related articles for article (PubMed ID: 22215147)
1. Increased expression of CD147 and MMP-9 is correlated with poor prognosis of salivary duct carcinoma.
Piao S; Zhao S; Guo F; Xue J; Yao G; Wei Z; Huang Q; Sun Y; Zhang B
J Cancer Res Clin Oncol; 2012 Apr; 138(4):627-35. PubMed ID: 22215147
[TBL] [Abstract][Full Text] [Related]
2. High expression of CD147 and MMP-9 is correlated with poor prognosis of triple-negative breast cancer (TNBC) patients.
Zhao S; Ma W; Zhang M; Tang D; Shi Q; Xu S; Zhang X; Liu Y; Song Y; Liu L; Zhang Q
Med Oncol; 2013 Mar; 30(1):335. PubMed ID: 23263825
[TBL] [Abstract][Full Text] [Related]
3. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases.
Jaehne M; Roeser K; Jaekel T; Schepers JD; Albert N; Löning T
Cancer; 2005 Jun; 103(12):2526-33. PubMed ID: 15900577
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of USP22 is associated with disease progression and patient prognosis of salivary duct carcinoma.
Piao S; Ma J; Wang W; Liu Y; Zhang M; Chen H; Guo F; Zhang B; Guo F
Oral Oncol; 2013 Aug; 49(8):796-801. PubMed ID: 23664741
[TBL] [Abstract][Full Text] [Related]
5. CD147, MMP9 expression and clinical significance of basal-like breast cancer.
Liu Y; Xin T; Jiang QY; Huang DY; Shen WX; Li L; Lv YJ; Jin YH; Song XW; Teng C
Med Oncol; 2013 Mar; 30(1):366. PubMed ID: 23292863
[TBL] [Abstract][Full Text] [Related]
6. Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: clinicopathological and prognostic implications.
Santana T; Pavel A; Martinek P; Steiner P; Grossmann P; Baněčková M; Skálová A
Hum Pathol; 2019 Nov; 93():37-47. PubMed ID: 31437521
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance.
Xu B; Dogan S; Haroon Al Rasheed MR; Ghossein R; Katabi N
Hum Pathol; 2019 Nov; 93():30-36. PubMed ID: 31430492
[TBL] [Abstract][Full Text] [Related]
8. The implications of TrkA and MET aberrations in de novo salivary duct carcinoma.
Ryu HJ; Koh YW; Yoon SO
Hum Pathol; 2018 Nov; 81():18-25. PubMed ID: 29753009
[TBL] [Abstract][Full Text] [Related]
9. Sarcomatoid variant of salivary duct carcinoma: clinicopathologic and immunohistochemical study of eight cases with review of the literature.
Nagao T; Gaffey TA; Serizawa H; Iwaya K; Watanabe A; Yoshida T; Yamazaki K; Sageshima M; Lewis JE
Am J Clin Pathol; 2004 Aug; 122(2):222-31. PubMed ID: 15323139
[TBL] [Abstract][Full Text] [Related]
10. Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review.
Uijen MJM; Lassche G; van Engen-van Grunsven ACH; Tada Y; Verhaegh GW; Schalken JA; Driessen CML; van Herpen CML
Cancer Treat Rev; 2020 Sep; 89():102069. PubMed ID: 32717621
[TBL] [Abstract][Full Text] [Related]
11. Expressions of CD147, MMP-2 and MMP-9 in laryngeal carcinoma and its correlation with poor prognosis.
Gou X; Chen H; Jin F; Wu W; Li Y; Long J; Gong X; Luo M; Bi T; Li Z; He Q
Pathol Oncol Res; 2014 Apr; 20(2):475-81. PubMed ID: 24357157
[TBL] [Abstract][Full Text] [Related]
12. Prediction of prognosis in gallbladder carcinoma by CD147 and MMP-2 immunohistochemistry.
Wu W; Wang R; Liu H; Peng J; Huang D; Li B; Ruan J
Med Oncol; 2009; 26(2):117-23. PubMed ID: 18665467
[TBL] [Abstract][Full Text] [Related]
13. [Survival analysis and immunohistochemical study of HER-2 and AR (androgen receptor) expression in salivary duct carcinoma].
Otsuka K; Imanishi Y; Habu N; Sato Y; Shigetomi S; Fujii R; Sakamoto K; Tomita T; Fujii M; Kameyama K; Ogawa K
Nihon Jibiinkoka Gakkai Kaiho; 2013 Sep; 116(9):1024-32. PubMed ID: 24191589
[TBL] [Abstract][Full Text] [Related]
14. Salivary Duct Carcinoma: An Update on Morphologic Mimics and Diagnostic Use of Androgen Receptor Immunohistochemistry.
Udager AM; Chiosea SI
Head Neck Pathol; 2017 Sep; 11(3):288-294. PubMed ID: 28321773
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of TRKB tyrosine kinase in the two histological types of parotid salivary duct carcinoma with cancer aggressiveness.
Moriwaki K; Ayani Y; Kuwabara H; Terada T; Higashino M; Kawata R
Oral Oncol; 2024 Apr; 151():106751. PubMed ID: 38479153
[TBL] [Abstract][Full Text] [Related]
16. Osteoclast-type giant cell tumor of minor salivary gland with mucin-rich salivary duct carcinoma: a case report of unusual histology with immunohistochemical analysis.
Kusafuka K; Nakamura S; Asano R; Kamijo T; Iida Y; Onistuka T; Nakajima T
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Jun; 109(6):870-7. PubMed ID: 20346712
[TBL] [Abstract][Full Text] [Related]
17. Brain metastases in patients with salivary duct carcinoma: A retrospective study.
Fushimi C; Takahashi H; Kawakita D; Kano S; Tsukahara K; Ozawa H; Okami K; Sakai A; Yamazaki K; Okada T; Hanazawa T; Sato Y; Imanishi Y; Shimizu A; Matsuki T; Nagao T; Tada Y
Cancer Med; 2024 Mar; 13(5):e7037. PubMed ID: 38477487
[TBL] [Abstract][Full Text] [Related]
18. Genomic alteration in rare subtype of sarcomatoid salivary duct carcinoma.
Jeong JS; Cho KJ; Kim D; Lee YS; Song JS
Pathol Res Pract; 2021 Dec; 228():153678. PubMed ID: 34781210
[TBL] [Abstract][Full Text] [Related]
19. Salivary duct carcinoma with rhabdoid features: a salivary counterpart of pleomorphic lobular carcinoma of the breast.
Kusafuka K; Kawasaki T; Maeda M; Yamanegi K; Baba S; Ito Y; Inagaki H; Nakajima T
Histopathology; 2017 Jan; 70(2):164-173. PubMed ID: 27079821
[TBL] [Abstract][Full Text] [Related]
20. Survival rates and prognostic factors for infiltrating salivary duct carcinoma: Analysis of 228 cases from the Surveillance, Epidemiology, and End Results database.
Jayaprakash V; Merzianu M; Warren GW; Arshad H; Hicks WL; Rigual NR; Sullivan MA; Seshadri M; Marshall JR; Cohan DM; Zhao Y; Singh AK
Head Neck; 2014 May; 36(5):694-701. PubMed ID: 23606370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
